Rezurock™ (belumosudil) – New orphan drug approval
July 16, 2021 - Kadmon Pharmaceuticals announced the FDA approval of Rezurock (belumosudil), for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GvHD) after failure of at least two prior lines of systemic therapy.
Top